Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death

Cytokine

Volumn 60, Issue 2, 2012, Pages 321-327

  Heinhuis, Bas ^a   Netea, Mihai G ^a   van den Berg, Wim B ^a   Dinarello, Charles A ^a,b   Joosten, Leo A B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Autoimmune diseases; Cell death; Cytokines; IL 32; Inflammation

Indexed keywords

BETA INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOKINE; FOCAL ADHESION KINASE 1; INTEGRIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 32 ALPHA; INTERLEUKIN 32 BETA; INTERLEUKIN 32 DELTA; INTERLEUKIN 32 GAMMA; INTERLEUKIN 33; INTERLEUKIN 37; MATRIX METALLOPROTEINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; CELL ACTIVATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; CELL DEATH; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKINS; INTRACELLULAR SPACE;

EID: 84866751724     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.010     Document Type: Review

References (64)

1. Dahl C.A., Schall R.P., He H.L., Cairns J.S. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992, 148:597-603.
2. D'Souza S.E., Ginsberg M.H., Plow E.F. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991, 16:246-250.
3. Ruoslahti E., Pierschbacher M.D. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986, 44:517-518.
4. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
5. Goda C., Kanaji T., Kanaji S., Tanaka G., Arima K., Ohno S., et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006, 18:233-240.
6. Choi J.D., Bae S.Y., Hong J.W., Azam T., Dinarello C.A., Her E., et al. Identification of the most active interleukin-32 isoform. Immunology 2008, 126:535-542.
7. Heinhuis B., Koenders M.I., van de Loo F.A., Netea M.G., van den Berg W.B., Joosten L.A. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA 2011, 108:4962-4967.
8. Netea M.G., Azam T., Lewis E.C., Joosten L.A., Wang M., Langenberg D., et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 2006, 3:e277.
9. Alsaleh G., Sparsa L., Chatelus E., Ehlinger M., Gottenberg J.E., Wachsmann D., et al. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010, 12:R135.
10. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., Deeg H.J. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008, 105:2865-2870.
11. Shioya M., Nishida A., Yagi Y., Ogawa A., Tsujikawa T., Kim-Mitsuyama S., et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007, 149:480-486.
12. Shoda H., Fujio K., Yamaguchi Y., Okamoto A., Sawada T., Kochi Y., et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006, 8:R166.
13. Bai X., Kim S.H., Azam T., McGibney M.T., Huang H., Dinarello C.A., et al. IL-32 is a host protective cytokine against mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol 2010, 184:3830-3840.
14. Heinhuis B., Koenders M.I., van de Loo F.A., van Lent P.L., Kim S.H., Dinarello C.A., et al. IL-32{gamma} and streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2. Ann Rheum Dis 2010, 69:1866-1872.
15. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009, 10:1073-1080.
16. Rasool S.T., Tang H., Wu J., Li W., Mukhtar M.M., Zhang J., et al. Increased level of IL-32 during human immunodeficiency virus infection suppresses HIV replication. Immunol Lett 2008, 117:161-167.
17. Nold M.F., Nold-Petry C.A., Pott G.B., Zepp J.A., Saavedra M.T., Kim S.H., et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008, 181:557-565.
18. Li W., Liu Y., Mukhtar M.M., Gong R., Pan Y., Rasool S.T., et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE 2008, 3:e1985.
19. Li W., Sun W., Liu L., Yang F., Li Y., Chen Y., et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol 2010, 185:5056-5065.
20. Inohara N., Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003, 3:371-382.
21. Strober W., Murray P.J., Kitani A., Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9-20.
22. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010, 11:373-384.
23. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Walsh M., Park J.S., et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005, 102:16309-16314.
24. Heinhuis B., Koenders M.I., van Riel P.L., van de Loo F.A., Dinarello C.A., Netea M.G., et al. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis 2010, 70:660-667.
25. Courties G., Presumey J., Duroux-Richard I., Jorgensen C., Apparailly F. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009, 9:535-538.
26. Courties G., M B., Presumey J., Escriou V., Van L.P., Scherman D., et al. Cytosolic phospholipase A2alpha gene silencing in the myeloid lineage alters development of Th1 responses and reduces autoimmune arthritis. Arthritis Rheum 2010.
27. Duroux-Richard I., Presumey J., Courties G., Gay S., Gordeladze J., Jorgensen C., et al. MicroRNAs as new player in rheumatoid arthritis. Joint Bone Spine 2011, 78:17-22.
28. Huber L.C., Distler O., Gay R.E., Gay S. Antisense strategies in degenerative joint diseases: sense or nonsense?. Adv Drug Deliv Rev 2006, 58:285-299.
29. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59-67.
30. Presumey J., Duroux-Richard I., Courties G., Apparailly F. Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. Curr Opin Mol Ther 2010, 12:325-330.
31. Cagnard N., Letourneur F., Essabbani A., Devauchelle V., Mistou S., Rapinat A., et al. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005, 16:289-292.
32. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006, 103:3298-3303.
33. Barrera P., Joosten L.A., den Broeder A.A., van de Putte L.B., van Riel P.L., van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:660-669.
34. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545.
35. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
36. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
37. Hong J., Bae S., Kang Y., Yoon D., Bai X., Chan E.D., et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine 2010, 49:171-176.
38. Calabrese F., Baraldo S., Bazzan E., Lunardi F., Rea F., Maestrelli P., et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178:894-901.
39. Kobayashi H., Lin P.C. Molecular characterization of IL-32 in human endothelial cells. Cytokine 2009, 46:351-358.
40. Kobayashi H., Yazlovitskaya E.M., Lin P.C. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int J Radiat Oncol Biol Phys 2009, 74:1573-1579.
41. Kobayashi H., Huang J., Ye F., Shyr Y., Blackwell T.S., Lin P.C. Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS ONE 2010, 5:e9458.
42. Green D.R., Droin N., Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003, 193:70-81.
43. Heinhuis B., Koenders M.I., van den Berg W.B., Netea M.G., Dinarello C.A., Joosten L.A. IL-32 contains a typical alpha-helix bundle structure that resembles the focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem 2012, 287:5733-5743.
44. Majid S., Dar A.A., Saini S., Yamamura S., Hirata H., Tanaka Y., et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010, 116:5637-5649.
45. Nishida A., Andoh A., Inatomi O., Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem 2009, 284:17868-17876.
46. Seo E.H., Kang J., Kim K.H., Cho M.C., Lee S., Kim H.J., et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 2008, 18:1606-1612.
47. Sorrentino C., Di C.E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009, 180:769-779.
48. Cheon S., Lee J.H., Park S., Bang S.I., Lee W.J., Yoon D.Y., et al. Overexpression of IL-32{alpha} increases NK cell-mediated killing through up-regulation of Fas and ULBP2 expression in human chronic myeloid leukemia cells. J Biol Chem 2011.
49. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
50. Giancotti F.G., Ruoslahti E. Integrin signaling. Science 1999, 285:1028-1032.
51. Abram C.L., Lowell C.A. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 2009, 27:339-362.
52. Buckley C.D., Pilling D., Henriquez N.V., Parsonage G., Threlfall K., Scheel-Toellner D., et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999, 397:534-539.
53. Roy A., Kucukural A., Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010, 5:725-738.
54. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008, 9:40.
55. Tachibana K., Sato T., D'Avirro N., Morimoto C. Direct association of pp 125FAK with paxillin, the focal adhesion-targeting mechanism of pp125FAK. J Exp Med 1995, 182:1089-1099.
56. Mortier E., Cornelissen F., van H.C., Dillen L., Richardson A. The focal adhesion targeting sequence is the major inhibitory moiety of Fak-related non-kinase. Cell Signal 2001, 13:901-909.
57. Kim Y.G., Lee C.K., Oh J.S., Kim S.H., Kim K.A., Yoo B. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum 2010, 62:515-523.
58. Mabilleau G., Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE 2009, 4:e4173.
59. Meyer N., Zimmermann M., Burgler S., Bassin C., Woehrl S., Moritz K., et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol 2010, 125:858-865.
60. Netea M.G., Lewis E.C., Azam T., Joosten L.A., Jaekal J., Bae S.Y., et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 2008, 105:3515-3520.
61. Nold-Petry C.A., Nold M.F., Zepp J.A., Kim S.H., Voelkel N.F., Dinarello C.A. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci USA 2009, 106:3883-3888.
62. Hasegawa H., Thomas H.J., Schooley K., Born T.L. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein. Cytokine 2011, 53:74-83.
63. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
64. Jiang W., Pisetsky D.S. Mechanisms of disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis. Nat Clin Pract Rheumatol 2007, 3:52-58.